Grignard Pure is a revolutionary technology that puts a barrier between the source of airborne pathogens and mold for disease mitigation and mold control.
The Grignard Pure technology is effective against a host of airborne pathogens and mold (fungi) including but limited to SARS CoV 19, Influenza, Avian Flu, TB, Listeria, Salmonella, MRSA, Mold (Fungi) Spores, Common Cold, Pseudonymous. The Grignard Pure technology has been verified in peer reviewed papers, GLP testing and proof of concept testing.
The market size is greater than $225 billion for which the analytics for this new space is available.
We have received the first two regulatory approvals for commercialization scheduled for Q3 of 2023 through a Blackstone company.
The science and engineering team are all leaders in their fields from leading academic and business institutions including Harvard, Oxford, Johns Hopkins, Rutgers, NYU, JBB, STV, ME Engineering. The experience of the team is available in the pitch deck.
The financing asks are:
1) Close out the initial financing for which $625,000 is available for commercialization into the mold control space.
Ready to Ask For Funding for your company?
Post a Funding Request